Technical Analysis for CVAC - CureVac N.V.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 2.88 | -3.68% | -0.11 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 50 DMA | Bearish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Crossed Above 50 DMA | Bullish | -3.68% | |
Weak + Overbought | Other | -3.68% | |
Inside Day | Range Contraction | -3.68% | |
Wide Bands | Range Expansion | -3.68% | |
Gapped Up | Strength | -3.68% | |
Overbought Stochastic | Strength | -3.68% |
Alert | Time |
---|---|
Possible NR7 | about 18 hours ago |
60 Minute Opening Range Breakdown | about 21 hours ago |
Down 3% | about 23 hours ago |
Fell Below 50 DMA | about 23 hours ago |
Fell Below Previous Day's Low | about 23 hours ago |
Get a Trading Sidekick!
- Earnings date: 06/18/2024
CureVac N.V. Description
CureVac B.V., a clinical-stage biopharmaceutical company, engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102 that is in a Phase I clinical trial for the treatment of various types of solid tumors; and CV7202, which is investigating in a Phase I clinical trial for vaccination against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase I clinical trial. The company has collaboration and license agreements with GlaxoSmithKline Biologicals SA, Genmab B.V., Boehringer Ingelheim GmbH, and Eli Lilly and Company; development and option agreements with Arcturus Therapeutics, Inc., Acuitas Therapeutics Inc., and CRISPR Therapeutics AG; and a development and intellectual property agreement with Tesla Grohmann Automation GmbH. CureVac B.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pharmaceutical Solid Tumors Acid Health Care Coronavirus Vaccination CRISPR Rabies Arcturus Therapeutics Genmab
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 12.36 |
52 Week Low | 2.215 |
Average Volume | 771,212 |
200-Day Moving Average | 5.20 |
50-Day Moving Average | 2.97 |
20-Day Moving Average | 2.67 |
10-Day Moving Average | 2.70 |
Average True Range | 0.20 |
RSI (14) | 52.83 |
ADX | 25.79 |
+DI | 24.65 |
-DI | 18.86 |
Chandelier Exit (Long, 3 ATRs) | 2.55 |
Chandelier Exit (Short, 3 ATRs) | 2.82 |
Upper Bollinger Bands | 3.12 |
Lower Bollinger Band | 2.21 |
Percent B (%b) | 0.73 |
BandWidth | 34.25 |
MACD Line | -0.02 |
MACD Signal Line | -0.09 |
MACD Histogram | 0.0755 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.10 | ||||
Resistance 3 (R3) | 3.12 | 3.06 | 3.07 | ||
Resistance 2 (R2) | 3.06 | 3.00 | 3.05 | 3.05 | |
Resistance 1 (R1) | 2.97 | 2.97 | 2.94 | 2.95 | 3.04 |
Pivot Point | 2.91 | 2.91 | 2.90 | 2.90 | 2.91 |
Support 1 (S1) | 2.82 | 2.85 | 2.79 | 2.81 | 2.72 |
Support 2 (S2) | 2.76 | 2.82 | 2.75 | 2.71 | |
Support 3 (S3) | 2.67 | 2.76 | 2.69 | ||
Support 4 (S4) | 2.66 |